The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma

BACKGROUND: We investigated the treatment outcomes and hepatic reserve of transarterial chemoembolization (TACE)-refractory patients with recurrent advanced hepatocellular carcinoma (HCC) treated with TACE plus sorafenib. METHODS: Forty-one patients with intermediate-stage HCC defined as being TACE...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaibori, Masaki, Matsushima, Hideyuki, Ishizaki, Morihiko, Kosaka, Hisashi, Matsui, Kosuke, Kariya, Shuji, Yoshii, Kengo, Sekimoto, Mitsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325117/
https://www.ncbi.nlm.nih.gov/pubmed/33906315
http://dx.doi.org/10.31557/APJCP.2021.22.4.1217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325117/
https://www.ncbi.nlm.nih.gov/pubmed/33906315
http://dx.doi.org/10.31557/APJCP.2021.22.4.1217

Ejemplares similares